Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080948 · ClinicalTrials.gov registry record
Risk Stratification Among Individuals Who Have Many Moles on Their Skin
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 73
- Enrollment target
NCT03080948: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03080948 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03080948 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 73 participants
- Enrollment target
Study Summary
The investigators are doing this study to improve our ability to identify which people with many moles on their skin are most likely to develop skin melanoma. The investigators hope to identify features of moles that are associated with melanoma risk. The investigators hope to use this information to customize and tailor melanoma screening to the individual patient based on a better estimate of their individual risk.
Primary Outcome
For each person, the proportions of their nevi having specific dermoscopic patterns will be calculated.
Interventions
- BEHAVIORAL survey
- OTHER Saliva samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2017-03-09 |
| Est. Completion | 2025-11-28 |
What the finished NCT03080948 record still lists
NCT03080948 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which survey is the first listed.
NCT03080948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03080948 about?
NCT03080948 is a clinical study titled "Risk Stratification Among Individuals Who Have Many Moles on Their Skin". The investigators are doing this study to improve our ability to identify which people with many moles on their skin are most likely to develop skin melanoma. The investigators hope to identify features of moles that are associated with melanoma risk. The investigators hope to use this information t...
What is the current status of trial NCT03080948?
This trial is currently completed. The enrollment target is 73 participants. The study started on 2017-03-09. Estimated completion is 2025-11-28.
What interventions are being tested in trial NCT03080948?
The interventions under investigation include: survey (BEHAVIORAL), Saliva samples (OTHER).
Who is sponsoring clinical trial NCT03080948?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI